Limited Returns For Roche And AstraZeneca In Lung Cancer As NICE Restricts Tarceva And Iressa
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE’s decision to severely restrict second-line use of Roche’s Tarceva and AstraZeneca’s Iressa will not help distance the drugs sufficiently from a chasing pack, including Boehringer’s Giotrif.